Concord Biotech Limited (CONCORDBIO) Share Analysis
NSE · Healthcare · Pharmaceuticals
Concord Biotech Limited (NSE: CONCORDBIO) is an Indian listed company in the Pharmaceuticals sector and a constituent of NIFTY 500, NIFTY MidSmallcap 400, NIFTY Smallcap 250. As of 21 Sep 2026, the share price was ₹1,494.00, market capitalisation ₹15,634 Cr, P/E 56.3, ROE 12.5%.
Get the AI verdict on CONCORDBIO: BUY, BUY ON DIPS, WAIT or EXIT
Sign in for the full analysis — AI fundamental and technical analysis, recent news, and one verdict with an entry zone, two targets and a stop-loss, for a 3-month, 1-year, 3-year or 5-year horizon. A free plan is available.
Stored fundamentals as of 21 Sep 2026 — not a live quote. Signed-in analysis uses same-day data.
CONCORDBIO price and valuation
- Share price
- ₹1,494.00
- Market cap
- ₹15,634 Cr
- P/E ratio
- 56.3
- P/B ratio
- 7.74
- EPS
- ₹26.32
- Book value per share
- ₹193.00
- Dividend yield
- 0.51%
CONCORDBIO profitability and growth
- ROE
- 12.5%
- ROCE
- 17.1%
- Debt to equity
- 0
- Revenue growth (3 yr)
- 7%
- Revenue growth (5 yr)
- 11%
- Profit growth (3 yr)
- 0%
- Profit growth (5 yr)
- 1%
CONCORDBIO 52-week range
- 52-week high
- ₹1,695.00
- 52-week low
- ₹987.00
- Face value
- ₹1.00
CONCORDBIO shareholding pattern
- Promoters
- 44.08%
- FIIs
- 7.53%
- DIIs
- 9.37%
- Public
- 39.04%
Index membership: NIFTY 500, NIFTY MidSmallcap 400, NIFTY Smallcap 250.
Learn to read these numbers
- Metrics glossary — what P/E, ROE, ROCE and debt-to-equity mean.
- Investment Blogs — free lessons on fundamental and technical analysis.
- AI stock picks and Discover stocks by sector and index.
- How Stock-Analyze works — what the AI analysis and verdict cover.